Title | Evaluation of Matrix Metalloproteinase-2 (MMP-2) and -9 (MMP-9) and Their Tissue Inhibitors (TIMP-1 and TIMP-2) in Plasma from Patients with Neurodegenerative Dementia. |
Publication Type | Journal Article |
Year of Publication | 2018 |
Authors | Tuna, G, Yener, GGülmen, Oktay, G, İşlekel, GHüray, Kİrkalİ, FGüldal |
Journal | J Alzheimers Dis |
Volume | 66 |
Issue | 3 |
Pagination | 1265-1273 |
Date Published | 2018 |
ISSN | 1875-8908 |
Abstract | Matrix metalloproteinases (MMPs) are substantial regulators of learning and memory and might be involved in neurodegeneration. It is known that MMPs are involved in pathogenesis of Alzheimer's disease (AD) and are particularly involved in the amyloid-β processing pathway. However, information on circulating levels of these proteins and their tissue inhibitors (TIMPs) in AD and other neurodegenerative dementia (ND) diseases such as dementia with Lewy bodies (DLB) and frontotemporal dementia (FTD) is not clear. Therefore, this study was directed toward finding out how plasma levels of MMP-2, MMP-9, TIMP-1, and TIMP-2 vary in AD, DLB, and FTD; and investigating the correlation of the levels of MMPs and their inhibitors with clinical parameters of the patients. MMP-2, MMP-9, TIMP-1, and TIMP-2 levels were measured by enzyme linked immunosorbent assay (ELISA). Plasma MMP-2 levels were significantly lower in all the patient groups than in the age-matched healthy controls (HCs) (p |
DOI | 10.3233/JAD-180752 |
Alternate Journal | J. Alzheimers Dis. |
PubMed ID | 30412498 |